Anzeige
Mehr »
Dienstag, 13.05.2025 - Börsentäglich über 12.000 News
Wenn Rendite auf Sicherheit trifft: Warum Almonty Industries plötzlich jeder will!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
595 Leser
Artikel bewerten:
(2)

Scivita Medical enters into Strategic Agreement with Boston Scientific in China

Finanznachrichten News

SUZHOU, China, March 29, 2023 /PRNewswire/ -- Medical technology company Scivita Medical Technology Co., Ltd. ('Scivita Medical') and Boston Scientific (NYSE: BSX), one of the leading medical technology companies worldwide, have officially signed a Strategic Agreement forScivita's Single-Use Percutaneous Choledochoscope. Through this business cooperation and distribution agreement, Scivita Medical and Boston Scientific plan to establish a long-term partnership in the commercialization, marketing and promotion of Scivita's Single-Use Percutaneous Choledochoscope in China.

Signing ceremony

Under Scivita Medical's comprehensive product lineup of reusable endoscopes, single-use videoscopes and related systems and equipment, this cooperation further broadens its market penetration of its Single-Use Percutaneous Choledochoscope. Through the strong alliance with Boston Scientific, the penetration rate of the Single-Use Percutaneous Choledochoscope in China is expected to increase benefiting more hospitals and patients.

Single-Use Percutaneous Choledochoscope

Scivita Medical said, 'Thanks to Boston Scientific for its recognition of Scivita Medical. This is another important initiative for Scivita Medical in establishing its vision of becoming a global company, and another milestone following its strategic cooperation with Fujifilm for the European market. I believe this strategic cooperation with some of the world's leading medical technology companies and our company will accelerate the process of bringing China's medical innovations to the world.'

As a result of the growing demands of mitigating the risks of cross-contamination and hospital-acquired diseases, particularly amid the outbreak of COVID-19 pandemic, the global single-use videoscope market is also rapidly growing. The global market value of single-use videoscope was USD 0.5 billion in 2020, and is estimated to increase to USD 9.2 billion in 2030, according to Frost & Sullivan. Scivita Medical's single-use videoscopes have covered multiple clinical departments at a high risk of cross-infection, such as Gynecology, Respiratory, Urological Surgery and Hepatobiliary Surgery. Many of its products have already been approved in China, the United States, European Union (EU), Japan and other countries and regions.

Scivita Medical New Plant

This cooperation can be seen as strong evidence of Scivita Medical's comprehensive product lineup of reusable endoscopes, single-use videoscope and related systems and equipment, which further accelerates its commercialization and penetration in the field of single-use videoscope. In the future, Scivita Medical will further strengthen its innovation, improve market penetration by offering unique products and strive to become the preferred brand for doctors and patients worldwide.

About Scivita Medical

Founded in 2016, Scivita Medical is a medical device company that provides minimally invasive diagnosis and treatment solutions, and focuses on research, development and commercialization of medical endoscopes and related products. Scivita Medical takes 'Globalization' as its core strategy and has established R&D centers both in China and Japan. With solid in-house R&D capabilities, Scivita Medical has established a unique technology platform built upon five synergistic core technologies, and built a comprehensive portfolio of endoscope products and therapeutic products covering all types of endoscope procedures conducted by the various clinical departments, to address diverse medical needs. Adhering to its value of 'Clinical Focus' 'Collaborative Innovation' 'People Oriented' 'Excellence & Efficiency', Scivita Medical will continuously upgrade its core technologies, improve market penetration with excellent products aiming to become the preferred brand, trusted by doctors and patients around the world.

For more information, please visit: scivitamedical.com/#/

Photo - https://mma.prnewswire.com/media/2043103/Signing_ceremony.jpg
Photo - https://mma.prnewswire.com/media/2043104/Single_Use_Percutaneous_Choledochoscope.jpg
Photo - https://mma.prnewswire.com/media/2043105/1.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/scivita-medical-enters-into-strategic-agreement-with-boston-scientific-in-china-301784636.html

© 2023 PR Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.